Serum asprosin and trimethylamine oxide levels in polycystic over syndrome with and without metformin treatment

Authors : Koray KARAKULAK, Erhan ÖNALAN, Burkay YAKAR, Emir DÖNDER, Faruk KİLİNC, Mehmet Ferit GÜRSU

Pages : 781-788

Doi:10.17826/cumj.1217887

View : 26 | Download : 69

Publication Date : 2023-09-30

Article Type : Research Paper

Abstract :Purpose: The presence of a potential relationship between metabolic diseases and hormones and the intestinal flora has recently gained attention. Levels of asprosin and trimethylamine oxide insert ignore into journalissuearticles values(TMAO); may be associated with polycystic over syndrome insert ignore into journalissuearticles values(PCOS);, which is a metabolic disease. The present study aims to investigate the potential relationship of PCOS with serum asprosin and TMAO levels. Materials and Methods: This cross-sectional study included 30 PCOS patients on metformin, 30 PCOS patients not receiving treatment, and 30 healthy controls. The demographic, glucose, insulin resistance, lipid, and hormone profiles of the participants were analyzed. Serum asprosin and TMAO levels were investigated with the ELISA method. Results: Patients with PCOS had higher BMI, serum glucose, triglyceride, ALT, insulin levels, and HOMA-IR scores compared with controls. The serum testosterone level was 28.1 ng/dl in the control group, 33.3 ng/dl in the PCOS group receiving metformin and 48.0 ng/dl in the untreated PCOS group, and there was a statistically significant difference. Neither serum asprosin nor TMAO levels were significantly different when compared between the three groups. Conclusion: Serum asprosin and TMAO levels of individuals with PCOS and healthy controls were not significantly different. The receipt of metformin treatment by PCOS patients did not have a significant relationship with serum asprosin and TMAO levels.
Keywords : Polikistik over sendromu, trimetilamin n oksit, insülin direnci, gastrointestinal mikrobiyom